The Australian Government has announced a plan to improve how the TGA communicates with stakeholders just days after criticism about plans to increase fees.
Unilife has been granted a US patent for its prefilled syringe technology just weeks after announcing a supply contract with an unnamed autoimmune disease-focused pharma.
LabCorp moves closer to expanding central labs biz, Quintiles builds in Brazil, Synexus grows in South Africa and CRI opens new research facility - Welcome to Outsourcing-pharma.com’s round up of the latest news in the services space.
Ampac gets the OK from the DEA, Syngene lands PE-ED manufacturing contract and Great Southern is bought by Pernix Therapeutics – welcome to Outsourcing-pharma.com’s CMO round-up.
inVentiv Health’s medical management business – iMM – has partnered with patient behavioural counselling firm Vital Decisions to develop a care management and counselling programme for patients suffering from progressive disorders.
Dishman Pharmaceuticals has abandoned plans to set up a special economic zone (SEZ) citing law changes that make the project less attractive and unfavourable economics as the reasons for the decision.
Outsourcing-Pharma.com presents its latest round-up of the latest newcomers and career climbers in the world of pharmaceuticals, including news from AMRI, Ark, and IMC.
So far only Switzerland and Israel have asked to be included in the list of countries not required to provide written confirmation that plants making APIs destined for the EU meet the required standards according to an EC statement.
Prokarium – a biotech company that was formerly part of UK CMO Cobra Biologics spin-out - has bought an oral vaccine technology from Emergent BioSolutions.
An insomnia treatment linked to sleepwalking and sleep driving should stay on the market according to the Australian Therapeutic Good Administration (TGA).
No job losses, facility divestitures or strategic changes are planned at DPT Laboratories according to new owner Renaissance Pharma, which bought the CDMO in an out-of-the-blue deal last week.
in-PharmaTechnologist.com presents its weekly round-up of the latest chops and changes in the pharmaceutical industry, including news from the EMA, Cipla, and MethylGene.
The EMA wants a debate on the extrapolation of clinical data to see if a framework is needed to govern this potential approach to reducing unnecessary research and letting industry use resources more efficiently.
Argentina’s clinical trial market will hit $76m (EUR60.4) by 2015 with growth driven by low costs, a good regulatory environment and large patient populations, according to a new study.
Outsourcing-Pharma.com presents its weekly round-up of the changing faces in the world of pharmaceuticals, including news from Icon, NIH and Theradiag.
BASF has sold its chitosan biopolymers business to Norway-based Seagarden ASA continuing the divestiture of the non-core units it acquired as part of Cognis in 2010.
Outsourcing-Pharma.com presents a round-up of the latest contract manufacturing investments, including new screening services for Imaxio, Encap’s renewed push for its CMO biz, and Pernix’s bid to take over Great Southern Laboratories.
European laws on clinical trials need to be faster and more efficient but they are not the only reason for the decline in the sector according to EU health and consumer policy commissioner John Dalli.
A quarter of procedures carried out during clinical trials may be pointless according to a new study, which suggests that this unnecessary work costs around $5bn (€3.96bn) a year.
A new hand-held testing device can help drugmakers determine if their stainless steel tech is prone to corrosion according to developer Koslow Scientific.
in-PharmaTehcnologist.com presents its latest round-up of the new and changing faces of the pharmaceutical and biopharma world, including news from Transcept, Allegro and Sucampo.
A new draft guidance stating the level of insurance cover required for trial participants in the UK will accelerate ethics committees’ approval process, according to experts.
Scientists have uncovered a new simple way to “clean” genotoxic impurities (GTIs) in drug ingredients by mixing the solution with contamination-eating scavengers.
It seems service quality really does mean bigger profits for CROs serving the pharma and biopharma industries, according to Industry Standard Research’s (ISR) new report.
China-based Suzhou Pharma has set up a US regulatory and QA hub in what it says is a bid to provide Western cGMP (current good manufacturing practice) know-how with low cost Asian production.